CellCentric has secured $220 million in a Series D financing round to support the continued development of its lead candidate, inobrodib, and to initiate a pivotal Phase 3 trial in multiple myeloma. The funding represents the largest private biotech financing in Europe so far in 2026.
The company, which operates across the U.K. and U.S., plans to begin the Phase 3 study, named DOMMINO-2, in the second half of 2026. This trial will follow the ongoing Phase 2 DOMMINO-1 study, an open-label trial evaluating inobrodib in combination with standard-of-care therapies for patients with relapsed or refractory multiple myeloma. The Phase 2 study is currently enrolling participants, with primary results expected in 2029.
Inobrodib is an investigational small molecule designed to inhibit p300/CBP, targeting mechanisms associated with advanced blood cancers. CellCentric is developing the drug as a potential first-in-class oral therapy that can be administered at home, particularly for patients who have undergone multiple prior treatments. The company also intends to expand its research into additional combination regimens and maintenance therapy settings.
Data presented at the American Society of Hematology annual meeting indicated that the treatment demonstrated at least a twofold increase in response rates compared to existing therapies in patients previously treated with bispecific T cell engagers or anti-BCMA therapies. Additional Phase 2 findings shared in December showed that a 20-mg dose of inobrodib, used alongside pomalidomide and dexamethasone, produced similar improvements in heavily pretreated patients.
The Series D round was led by Venrock Healthcare Capital Partners, with participation from investors including Pfizer, Fidelity Management & Research Company, Sofinnova Partners, RA Capital Management, Forbion, HBM Healthcare, Avego Bioscience Capital, and American Cancer Society BrightEdge. According to the company, the financing was oversubscribed, with multiple term sheets declined during the process.
CellCentric CEO Will West stated that the funding provides sufficient resources to advance the drug through key development stages. He indicated that the capital would support two registration-enabling trials and broader clinical efforts without requiring immediate external partnerships. West also noted that the investor base could support a future initial public offering if pursued.
The company is currently enrolling patients in both the U.K. and the U.S. for its Phase 2 study, which examines the combination of inobrodib with pomalidomide and dexamethasone. The upcoming Phase 3 trial will expand the program globally. Additional studies are planned to explore the therapy’s use in other treatment combinations and settings.
West highlighted that a significant proportion of multiple myeloma patients receive care in community-based settings rather than large academic institutions, making an oral, at-home treatment approach relevant. He emphasized the drug’s tolerability profile and its potential role in later-line treatment options.
“What stands out with inobrodib is the consistency of clinical activity alongside a manageable safety profile in a heavily pretreated population,” said Ken Greenberg, partner at Venrock Healthcare Capital Partners.
CellCentric expects its current funding to sustain operations through 2029. While an IPO remains a possibility, the company is also considering alternative strategic options, including potential mergers or acquisitions.
CellCentric has successfully raised $220 million in a Series D financing round to accelerate the development of Inobrodib and support the launch of a Phase 3 clinical trial in multiple myeloma. The funding marks a major milestone for CellCentric as the company expands its oncology pipeline and advances next-generation cancer therapies.
CellCentric’s Series D Financing Round
The new investment provides CellCentric with significant capital to strengthen late-stage clinical development activities and expand operational capabilities. The financing round attracted strong participation from healthcare investors interested in innovative cancer therapeutics and epigenetic treatment strategies.
CellCentric plans to use the funding primarily to support regulatory preparation, global trial expansion, manufacturing readiness, and additional research initiatives.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
